HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Clinical Trial: New Myeloma Monoclonal Antibody in Phase I Study
Posted: Nov 04, 2017
Clinical Trial: New Myeloma Monoclonal Antibody in Phase I Study image

A Phase I study is open for an immunotherapy called GBR 1342 — based on Glenmark Pharmaceuticals’ proprietary BEAT technology platform. The drug is designed to activate the immune system by redirecting immune cells toward tumor tissue. It simultaneously engages CD38 and the CD3 molecule on T cells. GBR 1342 is a monoclonal antibody (which is the same treatment family as daratumumab and elotuzumab). The study will have two parts: 1) Doses will be escalated to determine the maximum tolerable dose and safety 2) An expansion cohort treated at the maximum dose will allow researchers to watch for efficacy for myeloma patients who are relapsed and refractory to today's myeloma treatments. The trial will be open at UAMS (Arkansas), Johns Hopkins (Baltimore), Hackensack (New Jersey) and Memorial Sloan Kettering Cancer Center (New York).

Learn more and connect with this trial directly here:

GBR 1342 Clinical Trial Find all eligible clinical trials for your myeloma here: Myeloma Clinical Trials

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube